210 related articles for article (PubMed ID: 15695799)
1. Kinetic modeling of 3'-deoxy-3'-fluorothymidine in somatic tumors: mathematical studies.
Muzi M; Mankoff DA; Grierson JR; Wells JM; Vesselle H; Krohn KA
J Nucl Med; 2005 Feb; 46(2):371-80. PubMed ID: 15695799
[TBL] [Abstract][Full Text] [Related]
2. Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer.
Muzi M; Vesselle H; Grierson JR; Mankoff DA; Schmidt RA; Peterson L; Wells JM; Krohn KA
J Nucl Med; 2005 Feb; 46(2):274-82. PubMed ID: 15695787
[TBL] [Abstract][Full Text] [Related]
3. Kinetic modeling of 3'-deoxy-3'-18F-fluorothymidine for quantitative cell proliferation imaging in subcutaneous tumor models in mice.
Kim SJ; Lee JS; Im KC; Kim SY; Park SA; Lee SJ; Oh SJ; Lee DS; Moon DH
J Nucl Med; 2008 Dec; 49(12):2057-66. PubMed ID: 18997037
[TBL] [Abstract][Full Text] [Related]
4. Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas.
Muzi M; Spence AM; O'Sullivan F; Mankoff DA; Wells JM; Grierson JR; Link JM; Krohn KA
J Nucl Med; 2006 Oct; 47(10):1612-21. PubMed ID: 17015896
[TBL] [Abstract][Full Text] [Related]
5. A simplified analysis of [18F]3'-deoxy-3'-fluorothymidine metabolism and retention.
Shields AF; Briston DA; Chandupatla S; Douglas KA; Lawhorn-Crews J; Collins JM; Mangner TJ; Heilbrun LK; Muzik O
Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1269-75. PubMed ID: 15991018
[TBL] [Abstract][Full Text] [Related]
6. 18F-fluorothymidine kinetics of malignant brain tumors.
Schiepers C; Chen W; Dahlbom M; Cloughesy T; Hoh CK; Huang SC
Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1003-11. PubMed ID: 17295039
[TBL] [Abstract][Full Text] [Related]
7. Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.
Bradbury MS; Hambardzumyan D; Zanzonico PB; Schwartz J; Cai S; Burnazi EM; Longo V; Larson SM; Holland EC
J Nucl Med; 2008 Mar; 49(3):422-9. PubMed ID: 18287265
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of 3'-deoxy-3'-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography.
Grierson JR; Schwartz JL; Muzi M; Jordan R; Krohn KA
Nucl Med Biol; 2004 Oct; 31(7):829-37. PubMed ID: 15464384
[TBL] [Abstract][Full Text] [Related]
9. Kinetic analysis of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy.
Menda Y; Boles Ponto LL; Dornfeld KJ; Tewson TJ; Watkins GL; Schultz MK; Sunderland JJ; Graham MM; Buatti JM
J Nucl Med; 2009 Jul; 50(7):1028-35. PubMed ID: 19525472
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution and uptake of 3'-deoxy-3'-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model.
Paproski RJ; Wuest M; Jans HS; Graham K; Gati WP; McQuarrie S; McEwan A; Mercer J; Young JD; Cass CE
J Nucl Med; 2010 Sep; 51(9):1447-55. PubMed ID: 20720035
[TBL] [Abstract][Full Text] [Related]
11. Application of a whole-body pharmacokinetic model for targeted radionuclide therapy to NM404 and FLT.
Grudzinski JJ; Floberg JM; Mudd SR; Jeffery JJ; Peterson ET; Nomura A; Burnette RR; Tomé WA; Weichert JP; Jeraj R
Phys Med Biol; 2012 Mar; 57(6):1641-57. PubMed ID: 22398155
[TBL] [Abstract][Full Text] [Related]
12. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
[TBL] [Abstract][Full Text] [Related]
13. 18F-Fluorothymidine radiation dosimetry in human PET imaging studies.
Vesselle H; Grierson J; Peterson LM; Muzi M; Mankoff DA; Krohn KA
J Nucl Med; 2003 Sep; 44(9):1482-8. PubMed ID: 12960196
[TBL] [Abstract][Full Text] [Related]
14. Parametric Method Performance for Dynamic 3'-Deoxy-3'-
Kramer GM; Frings V; Heijtel D; Smit EF; Hoekstra OS; Boellaard R;
J Nucl Med; 2017 Jun; 58(6):920-925. PubMed ID: 28572289
[TBL] [Abstract][Full Text] [Related]
15. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.
Ullrich R; Backes H; Li H; Kracht L; Miletic H; Kesper K; Neumaier B; Heiss WD; Wienhard K; Jacobs AH
Clin Cancer Res; 2008 Apr; 14(7):2049-55. PubMed ID: 18381944
[TBL] [Abstract][Full Text] [Related]
16. Tumor 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) uptake by PET correlates with thymidine kinase 1 expression: static and kinetic analysis of (18)F-FLT PET studies in lung tumors.
Brockenbrough JS; Souquet T; Morihara JK; Stern JE; Hawes SE; Rasey JS; Leblond A; Wiens LW; Feng Q; Grierson J; Vesselle H
J Nucl Med; 2011 Aug; 52(8):1181-8. PubMed ID: 21764789
[TBL] [Abstract][Full Text] [Related]
17. Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis.
Mankoff DA; Shields AF; Graham MM; Link JM; Eary JF; Krohn KA
J Nucl Med; 1998 Jun; 39(6):1043-55. PubMed ID: 9627342
[TBL] [Abstract][Full Text] [Related]
18. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs.
Schwartz JL; Tamura Y; Jordan R; Grierson JR; Krohn KA
J Nucl Med; 2003 Dec; 44(12):2027-32. PubMed ID: 14660729
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation.
Oyama N; Ponde DE; Dence C; Kim J; Tai YC; Welch MJ
J Nucl Med; 2004 Mar; 45(3):519-25. PubMed ID: 15001697
[TBL] [Abstract][Full Text] [Related]
20. The uptake of 3'-deoxy-3'-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels.
Barthel H; Perumal M; Latigo J; He Q; Brady F; Luthra SK; Price PM; Aboagye EO
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):257-63. PubMed ID: 15791434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
